Impact of Low Abundance HIV Variants on Response to Ritonavir-Boosted Atazanavir or Fosamprenavir Given Once Daily with Tenofovir/Emtricitabine in Antiretroviral-Naive HIV-Infected Patients

Population genotyping (PG) can underestimate resistance if resistance-containing low abundance variants go undetected. PG and clonal analysis (CA) results were compared in virologic failures (VFs) from a 48-week clinical trial that evaluated once-daily fosamprenavir/ritonavir (FPV/r) 1400 mg/100 mg...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Ross, Lisa L., Weinberg, Winkler G., DeJesus, Edwin, Fischl, Margaret A., Horton, Joseph H., Pappa, Keith A., Lancaster, C. Tracey, Pakes, Gary E., Smith, Kimberly Y.
Format: Artigo
Jezik:Inglês
Izdano: Mary Ann Liebert, Inc. 2010
Teme:
Preclinical Studies/Drug Development
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2875981/
https://ncbi.nlm.nih.gov/pubmed/20380480
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/aid.2009.0189
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items